Insiders · OVID

Bart Friedman

Director at Ovid Therapeutics Inc. (OVID)

Bart Friedman has filed 9 insider reports with the SEC since May 2021, as director at Ovid Therapeutics Inc. (OVID). The latest filing, on April 9, 2026, reports grant or award at Ovid Therapeutics Inc. (OVID).

Filings
9
Companies
1
Bought on market
None
Sold on market
None

Companies where Bart Friedman is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Ovid Therapeutics Inc. logo
OVID
Ovid Therapeutics Inc.
Director8,789$2.34Apr 9, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Bart Friedman with

Other insiders at the same companies

Questions about Bart Friedman

What is Bart Friedman's role at Ovid Therapeutics Inc.?
Bart Friedman reports to the SEC as director at Ovid Therapeutics Inc. (OVID), according to the latest filing on April 9, 2026.
How many shares does Bart Friedman own?
After the latest filing that states it, Bart Friedman directly owned 8,789 shares of Ovid Therapeutics Inc. (OVID). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Bart Friedman bought or sold stock recently?
No open-market purchases or sales by Bart Friedman are on file. The filings report grant or award.
How do I get alerts when Bart Friedman files?
Follow Bart Friedman on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Bart Friedman (SEC CIK 0001368324). Totals count each trade once, skipping amendments whose original is on file, from May 19, 2021 on. View on SEC EDGAR · Get this as JSON